LAMP einer der wenigen zukünftigen Überflieger - 500 Beiträge pro Seite

[b]TOBINb]]

So günstig bewertet daß man sich wundern muß warum der Kurs leider noch so niedrig ist.

Natürlich gibt es ein Risiko, wie bei jeder Aktie (s. Dt.Telekom etc.). Das ist aber begrenzt. In wenigen Wochen wird der Wert Beachtung finden.

@alle alten LAMP`ler und Hasen
Ihr wisst was ich meine. Man muß LAMP den wo-Usern regelrecht aufs Auge drücken. LAMP muß und wird in nächster Zeit über 4 Dollar gehen, damit sie an die Nasdaq kommt.

Tobin

[Birkenhonig]

@]bTOBINb]

...wobei das Risiko bei der DTE um einiges höher ist.
Ich glaube, Du weißt was ich meine.
LAMP wird seinen Weg gehen.
Ist nur im Moment halt etwas steinig.

Gruss
Birkenhonig

[js200]

@b)TOBINb)

Grausamer Name

Warum einen neuen Tread ???????

Die Meinungen sind besser auf einem Haufen, so wird wenigstens weniger übersehen!!!

JS200

[proFEiT]

@js200

Sei froh, daß der Tobin einen neuen Thread eröffnet hat.
Das war sicher für die anderen User, die noch online sind.

Der Wert muß jede Stunde in die Köpfe gepresst werden.
Das Ding muß hoch, wenns geht diesen Monat noch

[netta]

@ porFEiT
Hast wohl Dein Urlaubsgeld noch nicht zusammen, wie?

[js200]

LAMP - L.A.M. Pharmaceutical Corp (OTCBB : LAMP)

--------------------------------------------------------------------------------
VOLUME(-): LAMP Volume 87% > 20-adsv, Stock -5.06%



WEDNESDAY, JUNE 19, 2002 04:17 PM

This is the 1st VOLUME alert for LAMP in the past 7 calendar days.

Trading for L.A.M. Pharmaceutical Corp (OTCBB: LAMP) has been heavier than usual in today`s session. By 16:15 ET, the stock had already traded 269,200 shares via 101 trades. The cumulative volume is 86.50% above than its 20-day average of 144,340. Normally the stock experiences around 54 individual trades per session.

So far, today`s volume surge has caused a net decline in LAMP`s stock price. At the time of this alert, the stock was trading at $0.750, down $-0.040 (-5.06%).

One year ago, the Company`s shares closed at $0.870. The price has declined more than 13 percent since then.

Over the last 10 trading session LAMP has traded in a range between $0.790 and $1.010 and is currently trading 70.00% below its 52-week high of $2.500 set on April 18, 2002 and 70.45% above its 52-week low of $0.440 from January 22, 2002.

In the previous 3 sessions, LAMP trading has displayed a mixed trend. Closing results have been as follows:

June 17, 2002 --- closed at $0.842 up $0.012 (+1.45%) on 61,100 shares
June 14, 2002 --- closed at $0.830 down $0.020 (-2.35%) on 52,100 shares
June 13, 2002 --- closed at $0.850 down $0.050 (-5.56%) on 112,100 shares

The Company last released news on June 06, 2002:

"TheSUBWAY.com Announces Investment Opinion: Stocks to Watch Today!"

L.A.M. PHARMACEUTICAL CORP
LAM Pharmaceutical, Corp. is a biomedical company that developes novel transdermal drug delivery systems that offers patients safer and more effective treatment for a variety of serious diseases. The Company claims the technology is based on an original Ionic Polymer Matrix (IPM), a proprietary and patented combination of electrically charged and non-charged molecules with wound-healing properties.


JS200

[GSG9]

@TOBIN

Warum soll man einem glauben, der schon zu blöde ist sich eine ID anzulegen ?

[TomSec]

Tja und sei es durch einen Reverse-Split

[loss_pro]

ein nasdaq listing wäre imho erst 2003 erreichbar und bis dahin haben wir dann wahrscheinlich schon die bbx, da gibts soweit ich sehen kann keinen mindestkurs.

[js200]

F.D.A. Approved L.A.M. IPM Wound Gel(TM) Sales and Marketing to Begin in Early August 2002
26 Jun 2002, 07:01am ET
E-mail or Print this story
- - - - -

/FROM PR NEWSWIRE NEW YORK 800-776-8090/
[STK] LAMP
[IN] MTC HEA
[SU] OTC
TO BUSINESS AND MEDICAL EDITORS:

F.D.A. Approved L.A.M. IPM Wound Gel(TM)
Sales and Marketing to Begin in Early August 2002

LEWISTON, N.Y., June 26 /PRNewswire-FirstCall/ -- LAM Pharmaceutical,
Corp. (BB:LAMP; Frankfurt: LAM; Berlin: LAM)
(http://www.lampharm.com) announced today that it has completed its plans for
the marketing of its breakthrough wound care product, L.A.M. IPM Wound
Gel(TM).
The suggested price of a 10 gram tube (approximately 5 days supply), will
be US $55.00.
Distribution specialists are in place to ship and invoice the product to a
wide group of potential purchasers including:

* Home health care organizations
* Nursing homes
* Hospital wound care clinics
* Podiatrists
* Dermatologists
* Privately owned wound care clinics, and
* A significant number of the busiest office-based health care
professionals (in excess of 200,000).

Alan Drizen, CEO of LAM Pharmaceutical, Corp., said, "We are most pleased
to have scaled-up production, arranged for contract manufacturing under our
cognizance, and put a powerful marketing structure in place in such a short
time following the approval of L.A.M. IPM Wound Gel(TM) (April 15, 2002, FDA
Number K020325)."
Drizen went on to say, "We are especially pleased with the work of
RxCentric Inc. of New York City, who has created a brilliant first wave mini
infomercial for L.A.M. IPM Wound Gel(TM). We are convinced that those health
care professionals who view the 5-1/2 minute marketing message will understand
the product and appreciate its advantages quickly without taking valuable time
away from their busy practices."
Health care professionals may view the mini infomercial on email, CD ROM
or on various websites, following the product`s launch.
Sales and sample requests are expected to be brisk for L.A.M. IPM Wound
Gel(TM). The Company`s first scaled-up batch is fully committed to fill
requests for emergency use and numerous requests for samples from health care
professionals nation wide.
In addition, L.A.M. IPM Wound Gel(TM) is the first product to be judged
89% effective (clinical trial results available on written request) by leading
experts and opinion leaders in the fastest growing area of medicine.
L.A.M. IPM Wound Gel(TM) is approved for:

* Diabetic ulcers
* Venous stasis ulcers
* Pressure ulcers (including bed sores)
* Debrided wounds

Besides its unparalleled record in creating a suitable environment for
healing to take place (moist with essential enzyme and protein enhancement),
L.A.M. IPM Wound Gel(TM) has a most significant advantage over other leading
products -- economy!
L.A.M. IPM Wound Gel(TM) costs patients (many of whom are reimbursed) less
than US $12.00 a day.
Treatment of the most refractory (hard-to-heal) ulcers resulted in
satisfactory outcomes (89% effective) in 8.2 weeks in clinical trials.

For more information please email us at [e-mail].

Please visit our website http://www.lampharm.com for more information on
L.A.M. IPM Wound Gel(TM) and other LAM products.

About LAM Pharmaceutical, Corp.
LAM Pharmaceutical, Corp. is a biomedical company with laboratories in
Lewiston, New York, and a business office in Toronto. LAM focuses on the
development and commercialization of novel wound healing and transdermal drug
delivery systems that offer patients, among other benefits, safer and more
effective treatment for a variety of serious diseases. The technology is
based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M.
IPM(TM)), a proprietary and patented combination (a total of ten U.S. issued
and approved patents) of electrically charged and non-charged molecules with
wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for
use with well-established drugs, allowing for the sustained delivery of
greater amounts to the target areas than is otherwise possible by oral means,
thus prolonging therapeutic activity.
The main ingredient of the L.A.M. Ionic Polymer Matrix(TM) technology is a
derivative of hyaluronic acid, a molecule normally found in the skin, joints
and bones. Hyaluronic acid is a non-immunogenic (the body does not react to
it) and it is involved in such important biological functions as tissue
hydration and proteoglycan organization (formation of proteins and sugars) to
optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is
present in high concentrations in fetal skin where wound healing is rapid and
leaves little scarring.
L.A.M. IPM Wound Gel(TM) is a clear, viscous, aqueous, odorless gel
composed principally of sodium hyaluronate, a derivative salt of Hyaluronic
acid. L.A.M. IPM Wound Gel(TM) has demonstrated in both human and animal
trials to be of significant value in the management of certain skin ulcers and
wounds where maintaining a moist environment is supportive of the healing
process. In human skin, Hyaluronic acid is involved in such important
biological functions as tissue hydration and proteoglycan organization
(formation of proteins and sugars).
As of April 1, 2002, LAM had ten issued and allowed patents in the United
States. L.A.M. IPM Wound Gel(TM) is protected by one or more of the following
patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents
have been issued to L.A.M. Pharmaceutical, Corp. by the United States Patent
Office and have subsequently been filed on a global basis or are in the
process of global filing.

The Company`s list of products under development include the following:

L.A.M. IPM(TM) - Post Surgical Gel - An advanced L.A.M. IPM(TM) (ionic
polymer matrix) designed for use on fresh surgical wounds (stapled or sutured)
for the purpose of creating an environment conducive to improved healing.

L.A.M. IPM(TM) - Extreme Dry Skin Formula - A gel formula designed to
saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis
and extremely dry skin.

L.A.M. IPM(TM) - Female Sexual Dysfunction Matrix - a product that
provides enhanced lubrication while also allowing the external structures of
the female genitalia to be flushed with greater blood supply.

L.A.M. IPM(TM) - Motion Sickness Matrix - a product currently under
development, which is a topically applied delivery system, using a patch, of a
well-known motion sickness drug.

L.A.M. IPM(TM) - Arthritic Pain Matrix - is a clear aqueous gel that
contains a well proven off patent drug.

For more information please visit our website at http://www.lampharm.com
or send us an e-mail at [e-mail] to receive the latest information
and press releases.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are
trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents:
5,897,880; 6,120,804; 6,007,843; 6,063,405.

Statements in this press release regarding our business which are not
historical facts are "forward-looking statements" that involve risks and
uncertainties which could cause the Company`s actual results and financial
condition to differ materially from those anticipated by the forward-looking
statements. These risks and uncertainties include, but are not limited to
uncertainties relating to the need for additional funds and corporate
partners, product liability, dependence on third parties for manufacturing and
marketing, the early stage of products being marketed or under development,
patent risk and competition.

Company Contact: Joseph Slechta
Toll Free in N. America (877) LAM-7717
[phone]
Tel [phone]
Fax [phone]
Website: http://www.lampharm.com

Press Contact: Barry S. Kaplan
BARRY KAPLAN ASSOCIATES [phone]
FAX [phone]
Email: [e-mail]

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X71813740

JS200

[Paepstin]